# Ipamorelin FAQ: Direct Answers from the Research > Ipamorelin questions answered directly from the published record — detection, WADA status, half-life, the failed trial, the CJC-1295 pairing, appetite, and more. Cited where quantitative. Direct, cited answers drawn from the peer-reviewed record — no hype, no dosing advice. ## Is ipamorelin banned by WADA? Yes. Ipamorelin and other growth hormone secretagogues are prohibited in sport at all times under the World Anti-Doping Agency's category S2 [7]. The ban is enforceable in practice: analysts have identified even glycine-modified designer analogues of ipamorelin in seized doping material by mass spectrometry, showing detection methods extend beyond the plain compound [7]. ## Can ipamorelin be detected in a drug test? In an anti-doping test, yes. Accredited laboratories detect ipamorelin and its urinary metabolites using published methods — a direct-urine-injection technique screens it among 17 other prohibited small peptides at limits of detection of 50-500 pg/mL [9]. Because its terminal half-life is only about 2 hours [2], the drug clears quickly, but the detection window is far longer since labs target metabolites too [11]. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively triggers growth hormone release by activating the ghrelin / GHS-R1a receptor [1]. Its defining trait, established in 1998, is selectivity: it releases growth hormone potently without raising cortisol or prolactin even far above its active dose [1]. It is a research chemical, not an approved drug. ## What does ipamorelin do for you? In studies, ipamorelin triggers a single pulse of growth hormone by activating the ghrelin receptor, doing so selectively without spiking stress hormones [1]. Beyond that mechanism, proven human benefits are absent: its one human efficacy trial, for postoperative ileus, failed [3]. Reported effects like better sleep are anecdotal community accounts, not trial results — see the effects page. ## What is ipamorelin peptide? Ipamorelin peptide is a chain of five amino acids — sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — engineered for resistance to enzymatic breakdown and selective activation of the ghrelin (GHS-R1a) receptor on pituitary cells [1]. It is wholly synthetic, mimicking natural ghrelin's action, with a molecular weight of about 712 daltons. It has never been approved as a drug. ## What are the risks of ipamorelin? The honest answer is that ipamorelin's biggest risk is unknown long-term safety: its only Phase 2 trial ran just seven days and missed its endpoint [3], and no long-term human data exist. A class-level concern comes from a 28-day study of a related ghrelin-receptor agonist that found heart-muscle damage in rats [6]. Mechanistic cautions also apply for cancer, diabetes, and heart disease. ## Does ipamorelin reduce belly fat? There is no human evidence that ipamorelin reduces belly fat. The relevant data are animal-only: a 2024 ferret study found ipamorelin (1-3 mg/kg) inhibited chemotherapy-induced weight loss by about 24%, a protective effect against wasting rather than fat loss [5]. Community reports of a leaner appearance are anecdotal and confounded by diet and training — not a measured fat-loss outcome. ## What are the downsides of ipamorelin? The central downside is that the marketing far outpaces the evidence: the one human efficacy trial failed [3], and most claims rest on mechanism and short animal studies. Practical reported downsides include facial flushing, water retention, and increased hunger (all anecdotal). The deeper downside is uncharacterized long-term safety, against a class-level cardiac signal in a related compound [6]. ## Why is ipamorelin being discontinued? Ipamorelin was never a marketed drug to discontinue — its clinical development simply stopped after its only Phase 2 trial missed its primary endpoint for postoperative ileus (25.3 vs 32.6 hours to first tolerated meal, p=0.15) [3]. Separately, in 2024 the FDA removed ipamorelin acetate from the interim Section 503A bulk-substances list, tightening compounding-pharmacy access — which can read like a discontinuation. ## What does CJC-1295 and ipamorelin do? They raise growth hormone through two different receptors and are paired to exploit synergy: CJC-1295 mimics growth-hormone-releasing hormone while ipamorelin activates the ghrelin receptor [1]. In rats, GHRH and a GHRP given together produced growth-hormone peaks greater than the sum of each alone [12]. No controlled human trial of the combination exists for any outcome — the synergy is shown at the bench, not in people. ## Does ipamorelin increase IGF-1? Not reliably in short studies. Growth hormone normally drives the liver to make IGF-1, but a rat bone-growth study found ipamorelin raised longitudinal bone growth dose-dependently with no measurable change in total IGF-1 [4], suggesting a partly local, pulse-driven effect. Whether sustained human protocols meaningfully raise IGF-1 has not been characterized in controlled trials. ## How does CJC-1295 ipamorelin work? CJC-1295 acts on the GHRH receptor (mimicking growth-hormone-releasing hormone) while ipamorelin acts on the ghrelin / GHS-R1a receptor [1] — two distinct pathways. Blocking endogenous GHRH attenuates GHRP-induced growth-hormone release, so GHRH tone is required for full GHRP effect [13]. Combining a GHRH analog with a ghrelin-receptor agonist therefore produces a larger, synergistic growth-hormone pulse than either alone [12]. ## How much CJC-1295 ipamorelin should I take? No evidence-based dose exists. No controlled human trial of the ipamorelin and CJC-1295 combination has been run for any outcome; the pairing's rationale is mechanistic synergy shown in rodents [12]. Community "stack" protocols are anecdotal, have no peer-reviewed human dosing basis, and are not a recommendation. This site does not provide a dose because no published human dosing science supports one. ## Does CJC-1295 ipamorelin work? Mechanistically the pairing makes sense — combining a GHRH analog with a ghrelin-receptor agonist produces synergistic growth-hormone release in animals, greater than the sum of each alone [12]. Whether it "works" for a human goal like fat loss or muscle gain is untested: there is no controlled human trial of the combination for any outcome. Reported results are anecdotal and confounded by diet and training. ## How to reconstitute CJC-1295 ipamorelin 5mg? Only general peptide-handling description is supported, not a clinical preparation protocol. Ipamorelin is supplied as a lyophilized (freeze-dried) powder and, as a peptide, degrades with heat and freeze-thaw, so solutions are typically kept refrigerated for laboratory handling. This site provides no human-administration instructions; the only studied human routes were intravenous and supervised [2]. ## How long does ipamorelin stay in your system? Its terminal half-life in humans is about 2 hours, with the growth-hormone pulse peaking near 40 minutes after dosing [2] — so pharmacologically it clears within roughly a day. But the anti-doping detection window is longer, because labs screen for metabolites as well as the parent peptide [11], at picogram-per-milliliter sensitivity [9]. The half-life page covers both clocks in detail. ## Does ipamorelin make you hungry? It can, and the mechanism explains why: ipamorelin activates the ghrelin receptor, the same receptor that drives the body's "hunger" signal [1]. In community reports, increased appetite after injecting is occasionally reported and described as milder than with the older peptide GHRP-6 — anecdotal, not a measured trial outcome. No human study has quantified an appetite effect of ipamorelin at research-use doses. ## Will I gain weight on ipamorelin? There is no human trial answering this. Ipamorelin's only Phase 2 human study tested bowel recovery, not body weight, and failed its endpoint [3]. In animals it has shown both appetite-raising effects and, in a ferret model, protection against wasting [5]. Any weight change in community use is anecdotal and heavily confounded by diet, training, and concurrent compounds. ## Does ipamorelin increase appetite? Mechanistically, yes, it would be expected to: ipamorelin acts on the ghrelin (GHS-R1a) receptor, the body's primary appetite-driving receptor [1]. Community accounts occasionally report increased hunger after injecting, described as milder than older ghrelin-receptor peptides — but this is anecdotal experience. No controlled human study has measured an appetite change from ipamorelin at the doses used in the community. ## What does ipamorelin peptide do? Ipamorelin peptide selectively prompts the pituitary to release a pulse of growth hormone by activating the ghrelin / GHS-R1a receptor, without meaningfully raising cortisol or prolactin [1]. That selective growth-hormone release is its established action. Downstream human benefits are not proven — its one human efficacy trial failed [3] — and reported effects such as improved sleep are anecdotal community accounts. ## How long does it take for ipamorelin to work? Pharmacologically, fast: after dosing, the growth-hormone response is a single discrete pulse peaking about 40 minutes (0.67 h) later, with a roughly 2-hour terminal half-life [2]. That describes the hormonal response timing, not a human outcome benefit. Community reports of effects like improved sleep within one to two weeks are anecdotal and unverified, not measured study results. ## Does ipamorelin cause water retention? Mild water retention is occasionally reported in community accounts, typically in the first few weeks and described as milder than with older peptides — anecdotal, not a trial-measured effect. Mechanistically it is plausible: growth-hormone excess is associated with sodium and fluid retention. The only controlled human trial assessed bowel recovery, not fluid balance, and is not a source for this question [3]. --- An evidence-appraisal reading of the Ipamorelin record — the founding selectivity data weighed against the failed Phase 2 trial and the marketing, with the anti-doping detection science laid out plainly; no clinic behind the appraisal and nothing here dosed, dispensed, or sold.